WFDC2 and cystic fibrosis: Treatment with IVA previously lowered plasma HE4 levels in CF patients bearing a specific Class 3 CFTR pathogenic variant (Nagy et al., 2019), but no data were available on the impact of combined therapy in vivo with various CFTR correctors and modulators on plasma HE4 as yet.